English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Gastric cancer is one of the higher incidence cancers in gastrointestinal tumors, with obvious ethnic and geographical distributions (1). A total of 1,033,701 new cases were diagnosed in 2018, with an estimated 782,685 deaths, or 5.7% of the total number of cancer cases, accounting for 8.2% of total cancer deaths (1). More than 70% of new cases and deaths occur in developing countries, particularly in East Asia, Eastern Europe and South America (1). In China, a total of 405,000 new cases were diagnosed in 2012, with an estimated death toll of 325,000 cases (2). For patients with removable gastric cancer, the prognosis is poor, the overall survival rate is 5 years, about 20–30% (3). Previous studies have shown that the prognostic factors identified were infiltration depth, lymph Original Article

Elevated carbohydrate antigen 125 post-operation as a prognostic marker in gastric cancer patients with stage II–III